protein phosphatase, Mg2+/Mn2+ dependent 1N (putative)Genealiases: []
Q-omics provides the consensus-scored PPM1N profile across patient tissues and cancer cell-line models. PPM1N expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, PPM1N is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, PPM1N RNA expression shows 15,602 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, COAD, and UVM as cancer lineages where PPM1N shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPM1N — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPM1N survival associations across molecular data types. PPM1N RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPM1N RNA expression–survival associations across cancer types. High PPM1N expression shows unfavorable associations in KIRP, KIRC and COAD, but favorable associations in CESC, HNSC and SKCM. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for PPM1N RNA expression.
This table summarizes PPM1N tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for PPM1N. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPM1N shows lower tumor expression in KICH and higher tumor expression in COAD, KIRC, STAD, THCA and HNSC. The COAD box plot shows higher PPM1N RNA expression in tumor versus normal tissue (log2 FC = +1.250, t-test p < 0.001).
This table shows molecular features associated with PPM1N in patient tissues and cancer cell lines. In patient samples, PPM1N shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PPM1N RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and CNS.
